147378-74-3

Usage

Synthesis Reference(s)

Synthesis, p. 775, 1994 DOI: 10.1055/s-1994-25569

Upstream product

• 41661-47-6 piperidin-4-one 
• 401-78-5 3-bromo-1-trifluoromethylbenzene 
• 41979-39-9 4-piperidone hydrochloride 
• 598-54-9 copper (I) acetate 
• 121899-80-7 tris(3-trifluoro-methylphenyl)bismuthane 
• 98-16-8 3-trifluoromethylaniline 
• 72548-31-3 1,5-Dichloropentan-3-ol 
• 263008-86-2 2'-O-{4-Methoxy-1-[(3-trifluoromethyl)phenyl]piperidin-4-yl}uridine 
• 71989-92-9 1-(3-trifluoromethyl-phenyl)-piperidin-4-ol 

Downstream Products

• 1147864-77-4 8-chloro-5-(2-(6-methylpyridin-3-yl)ethyl)-2-(3-trifluoromethylphenyl)-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole 
• 147378-75-4 1-(3-Trifluoromethylphenyl)hexahydro-1,4-diazepin-5-one 
• 263008-86-2 2'-O-{4-Methoxy-1-[(3-trifluoromethyl)phenyl]piperidin-4-yl}uridine 
• 263008-79-3 4-Methoxy-1-[3-(trifluoromethyl)phenyl]-1,2,5,6-tetrahydropyridine 

Relevant academic research and scientific papers

Cobalt-Catalyzed Electrophilic Amination of Aryl- and Heteroarylzinc Pivalates with N-Hydroxylamine Benzoates

Aryl- and heteroarylzinc pivalates can be aminated with O-benzoylhydroxylamines at 25 °C within 2–4 h in the presence of 2.5–5.0 % CoCl2?2 LiCl to furnish the corresponding tertiary arylated or heteroarylated amines in good yields. This electrophilic amination also provides access to diarylamines and aryl(heteroaryl)amines. A new tuberculosis drug candidate (Q203) was prepared in six steps and 56 % overall yield by using this cobalt-catalyzed amination as the key step.

Some observations relating to the use of 1-aryl-4-alkoxypiperidin-4-yl groups for the protection of the 2′-hydroxy functions in the chemical synthesis of oligoribonucleotides

The comparative rates of acid-catalysed removal often 1-aryl-4-methoxypiperidin-4-yl 8 (R = Me) [including the previously reported Ctmp 5 and Fpmp 6] protecting groups for the 2′-hydroxy functions in oligoribonucleotide synthesis are discussed. These studies have led to the development of the 1-(4-chlorophenyl)-4-ethoxypiperidin-4-yl (Cpep) protecting group 8 (R = Et, R1 = R2 = H, R3 = Cl) which is both more stable than the Ctmp and Fpmp groups at pH 0.5 and more labile at pH 3.75. The influence of the ribonucleoside aglycone on the stability of the 2′-O-Fpmp and 2′-O-Ctmp protecting groups both at low and high pH is examined. The Royal Society of Chemistry 2000.

Synthesis of substituted N-arylpiperidines via organobismuth derivatives

The synthesis of N-arylpiperidines functionalized both on the aromatic and piperidine ring was performed using conveniently substituted triarylbismuthine derivatives as arylating agents. This method is, in particular, indicated to arylate the nitrogen atom of a secondary amine with a phenyl ring bearing electron-withdrawing groups in the m-position.

Benzimidazolone derivatives as 5-HT1A and 5-HT2 antagonists

Pharmacologically active benzimidazolone derivatives as 5-HT1Aand 5-HT2 receptors, useful in the treatment of CNS disorders of formula: wherein, R1 and R2 may be at the same time or not a hydrogen atom, halogen, trifluoromethyl, C1 6 alkyl, C1 6 alkoxy, C1 6 alkylthio, C1 6 acyl, carboxyl, C1 6 alkoxy- carbonyl, hydroxy, nitro, amino optionally C1 4 alkyl N-mono or di-substituted, C1 6 acylamino, C1 6 alkoxycarbonylamino, carbamoyl optionally C1 4 alkyl N-mono or di-substituted, cyano, C1 6 alkylsulphinyl, C1 6 alkylsulphonyl, amino sulphonyl optionally C1 4 alkyl N-mono or di-substituted, C1 4 alkyl N-mono or di-substituted aminosulphonylamino, aminosulphonylamino;, R3 is hydrogen, C1 6 alkyl, C2 6 alkenyl or C2-C6 alkynyl;, A is -CO- or -CONH- or it is absent;, B is a straight or branched, saturated or unsaturated C2 6 alkyl;, m and n are both independently an integer from 1 to 3;, R4 is an aryl, aralkyl, a heteroaryl or heteroaralkyl group, each group being optionally substituted by one or more substituents selected from halogen, trifluoromethyl, cyano, C1 3 alkoxy, C1 4 alkyland acid addition salts thereof., The process for the preparation of the compounds of formula I as well as pharmaceutical compositions containing them are also described.